- Home
- ETON vs TLSA Comparison
ETON vs TLSA Comparison
Compare ETON & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ETON | TLSA |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.8M | 200.8M |
| IPO Year | 2018 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ETON | TLSA |
|---|---|---|
| Price | $16.84 | $1.77 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $29.67 | N/A |
| AVG Volume (30 Days) | 277.8K | ★ 289.8K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $70,316,000.00 | N/A |
| Revenue This Year | $113.27 | N/A |
| Revenue Next Year | $36.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 102.77 | N/A |
| 52 Week Low | $11.09 | $0.63 |
| 52 Week High | $23.00 | $2.60 |
Technical Indicators
Market Signals| Indicator | ETON | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 50.49 |
| Support Level | $16.13 | $1.62 |
| Resistance Level | $17.05 | $1.82 |
| Average True Range (ATR) | 0.76 | 0.14 |
| MACD | 0.16 | 0.01 |
| Stochastic Oscillator | 79.06 | 60.84 |
Price Performance
Historical ComparisonAbout ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.